623.82
price down icon0.35%   -2.21
 
loading
Argen X Se Adr stock is traded at $623.82, with a volume of 264.34K. It is down -0.35% in the last 24 hours and up +5.41% over the past month. Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
See More
Previous Close:
$626.03
Open:
$623.2
24h Volume:
264.34K
Relative Volume:
1.05
Market Cap:
$37.30B
Revenue:
$1.86B
Net Income/Loss:
$-40.29M
P/E Ratio:
-149.96
EPS:
-4.16
Net Cash Flow:
$-1.28B
1W Performance:
+2.74%
1M Performance:
+5.41%
6M Performance:
+60.83%
1Y Performance:
+84.07%
1-Day Range:
Value
$619.60
$634.40
1-Week Range:
Value
$613.95
$644.97
52-Week Range:
Value
$327.73
$644.97

Argen X Se Adr Stock (ARGX) Company Profile

Name
Name
Argen X Se Adr
Name
Phone
-
Name
Address
-
Name
Employee
1,148
Name
Twitter
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
ARGX's Discussions on Twitter

Compare ARGX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ARGX
Argen X Se Adr
623.82 37.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.27 102.31B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
701.85 77.13B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.44 31.66B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.08 27.11B 3.30B -501.07M 1.03B -2.1146

Argen X Se Adr Stock (ARGX) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-12-24 Upgrade Wolfe Research Peer Perform → Outperform
Nov-05-24 Upgrade Scotiabank Sector Perform → Sector Outperform
Nov-01-24 Downgrade Robert W. Baird Outperform → Neutral
Nov-01-24 Upgrade William Blair Mkt Perform → Outperform
Oct-10-24 Resumed Raymond James Strong Buy
Oct-04-24 Downgrade Deutsche Bank Buy → Hold
Aug-06-24 Upgrade Barclays Equal Weight → Overweight
Jul-25-24 Upgrade Deutsche Bank Hold → Buy
Jul-23-24 Upgrade Oppenheimer Perform → Outperform
Feb-15-24 Initiated Wolfe Research Peer Perform
Dec-20-23 Downgrade Deutsche Bank Buy → Hold
Dec-20-23 Downgrade William Blair Outperform → Mkt Perform
Jul-31-23 Initiated Scotiabank Sector Perform
Jul-24-23 Downgrade UBS Buy → Neutral
Jul-17-23 Resumed Evercore ISI Outperform
Jun-15-23 Initiated Societe Generale Sell
May-31-23 Initiated UBS Buy
Apr-25-23 Initiated Citigroup Buy
Mar-14-23 Upgrade Robert W. Baird Neutral → Outperform
Dec-07-22 Initiated William Blair Outperform
Oct-12-22 Initiated Oppenheimer Perform
Jul-29-22 Downgrade Robert W. Baird Outperform → Neutral
Jun-28-22 Resumed Stifel Buy
May-03-22 Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-08-21 Initiated Wells Fargo Overweight
Nov-29-21 Upgrade Piper Sandler Neutral → Overweight
Oct-29-21 Upgrade Guggenheim Neutral → Buy
Oct-28-21 Upgrade Raymond James Outperform → Strong Buy
Oct-07-21 Initiated Jefferies Buy
Sep-23-21 Upgrade Redburn Neutral → Buy
Sep-07-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Jul-23-21 Initiated Deutsche Bank Hold
Jul-19-21 Resumed Wolfe Research Outperform
Jun-18-21 Initiated UBS Buy
Jun-04-21 Resumed Robert W. Baird Outperform
May-10-21 Upgrade H.C. Wainwright Neutral → Buy
Apr-23-21 Initiated Redburn Neutral
Mar-05-21 Reiterated H.C. Wainwright Neutral
Feb-02-21 Downgrade Piper Sandler Overweight → Neutral
Jan-04-21 Downgrade Guggenheim Buy → Neutral
Aug-25-20 Initiated Raymond James Outperform
Aug-19-20 Downgrade Evercore ISI Outperform → In-line
Jul-29-20 Initiated H.C. Wainwright Neutral
Feb-10-20 Initiated BofA/Merrill Buy
Nov-05-19 Initiated Credit Suisse Neutral
Oct-31-19 Upgrade William Blair Mkt Perform → Outperform
Oct-22-19 Initiated JP Morgan Overweight
Sep-27-19 Initiated Wells Fargo Market Perform
Sep-16-19 Resumed Cowen Outperform
Jun-28-19 Initiated Robert W. Baird Outperform
Jan-18-19 Resumed SunTrust Buy
Jan-04-19 Initiated Morgan Stanley Overweight
Dec-17-18 Initiated Goldman Buy
Dec-14-18 Initiated Wolfe Research Outperform
Jun-29-18 Initiated Nomura Buy
Apr-09-18 Initiated SunTrust Buy
Jan-29-18 Reiterated JMP Securities Mkt Outperform
View All

Argen X Se Adr Stock (ARGX) Latest News

pulisher
Dec 16, 2024

Argenx stock soars to all-time high of $630.4 amid robust growth By Investing.com - Investing.com South Africa

Dec 16, 2024
pulisher
Dec 16, 2024

Argenx stock soars to all-time high of $630.4 amid robust growth - Investing.com

Dec 16, 2024
pulisher
Dec 15, 2024

argenx's SWOT analysis: biotech stock soars on VYVGART success - Investing.com

Dec 15, 2024
pulisher
Dec 12, 2024

Upcoming Nasdaq-100 changes could boost the stocks of these 11 companies - Yahoo Finance

Dec 12, 2024
pulisher
Dec 11, 2024

Idiopathic Inflammatory Myositis Industry Assessment, 2020-2034: Breakthrough Therapies (Dazukibart and Efgartigimod) Propel Market Expansion Across the 7MM - GlobeNewswire Inc.

Dec 11, 2024
pulisher
Dec 09, 2024

Argenx Expands Autoimmune Portfolio With Additional Vyvgart Approvals as Pipeline Develops - Morningstar

Dec 09, 2024
pulisher
Dec 09, 2024

Piper Sandler maintains stock target on argenx, cites growth potential - Investing.com

Dec 09, 2024
pulisher
Dec 02, 2024

Argenx stock soars to all-time high of $620.29 - Investing.com

Dec 02, 2024
pulisher
Nov 30, 2024

10 High Growth Healthcare Stocks to Invest in Now - Insider Monkey

Nov 30, 2024
pulisher
Nov 26, 2024

Argenx stock soars to all-time high of $612.64 amid robust growth By Investing.com - Investing.com South Africa

Nov 26, 2024
pulisher
Nov 26, 2024

Argenx stock soars to all-time high of $612.64 amid robust growth - Investing.com India

Nov 26, 2024
pulisher
Nov 25, 2024

argenx's SWOT analysis: biotech firm's stock soars on VYVGART success - Investing.com

Nov 25, 2024
pulisher
Nov 25, 2024

Jefferies reaffirms Buy rating on argenx stock, ups target amid promising trial updates - Investing.com India

Nov 25, 2024
pulisher
Nov 21, 2024

Can Argenx stock sustain its autoimmune category dominance? Oppenheimer weighs in - Investing.com

Nov 21, 2024
pulisher
Nov 21, 2024

Barclays bullish on argenx stock after positive trial results - Investing.com

Nov 21, 2024
pulisher
Nov 21, 2024

Barclays bullish on argenx stock after positive trial results By Investing.com - Investing.com South Africa

Nov 21, 2024
pulisher
Nov 20, 2024

argenx shares see price target boosted by Raymond James, Strong Buy rating upheld - Investing.com

Nov 20, 2024
pulisher
Nov 18, 2024

10 Biggest Biotechnology Companies - Investopedia

Nov 18, 2024
pulisher
Nov 12, 2024

Argenx upgraded at Wolfe on myasthenia gravis dominance - MSN

Nov 12, 2024
pulisher
Nov 12, 2024

argenx stock boosted by Wolfe, citing dominance in MG and profitability ahead - Investing.com

Nov 12, 2024
pulisher
Nov 11, 2024

Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China - Yahoo Finance

Nov 11, 2024
pulisher
Nov 05, 2024

Scotiabank raises argenx stock PT to $715, highlights efgartigimod's potential - Investing.com India

Nov 05, 2024
pulisher
Nov 05, 2024

argenx SE's SWOT analysis: biotech stock poised for growth amid challenges - Investing.com

Nov 05, 2024
pulisher
Nov 04, 2024

Deutsche Bank raises argenx target by EUR25, acknowledges momentum despite valuation - Investing.com

Nov 04, 2024
pulisher
Nov 01, 2024

Argenx shares target raised by H.C. Wainwright, citing strong sales performance - Investing.com

Nov 01, 2024
pulisher
Nov 01, 2024

Argenx Q3 Revenue, EPS Beats Excite Bullish Biotech Analysts: 'Most Enviable I&I Pipeline In Entire Industry' - Benzinga

Nov 01, 2024
pulisher
Nov 01, 2024

Argenx shares target lifted, overweight on Vyvgart sales beat - Investing.com

Nov 01, 2024
pulisher
Nov 01, 2024

argenx stock downgraded after 65% rally, Baird cites limited short-term upside - Investing.com India

Nov 01, 2024
pulisher
Nov 01, 2024

William Blair bullish on argenx stock as Vyvgart flexes in CIDP and eyes new horizons - Investing.com India

Nov 01, 2024
pulisher
Nov 01, 2024

Raymond James maintains outperform on argenx, cites strong sales - Investing.com India

Nov 01, 2024
pulisher
Nov 01, 2024

argenx stock climbs as Truist highlights industry-leading I&I pipeline growth - Investing.com India

Nov 01, 2024
pulisher
Nov 01, 2024

Stifel sees upside in argenx stock with robust pipeline and solid 3Q results - Investing.com

Nov 01, 2024
pulisher
Oct 31, 2024

Earnings call: argenx sees growth with VYVGART, sets sights on CIDP - Investing.com Nigeria

Oct 31, 2024
pulisher
Oct 31, 2024

Earnings call: argenx sees growth with VYVGART, sets sights on CIDP By Investing.com - Investing.com South Africa

Oct 31, 2024
pulisher
Oct 31, 2024

Argenx stock soars to all-time high of $589.6 amid robust growth - Investing.com

Oct 31, 2024
pulisher
Oct 31, 2024

argenx ADR earnings beat by $1.24, revenue topped estimates - Investing.com

Oct 31, 2024
pulisher
Oct 30, 2024

argenx Reports Third Quarter 2024 Financial Results and Provides Business Update - Yahoo Finance

Oct 30, 2024
pulisher
Oct 24, 2024

argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024 - The Bakersfield Californian

Oct 24, 2024
pulisher
Oct 23, 2024

argenx SE's SWOT analysis: biotech firm's stock poised for growth amid challenges - Investing.com

Oct 23, 2024
pulisher
Oct 21, 2024

Weekly Upgrades and Downgrades - InvestorPlace

Oct 21, 2024
pulisher
Oct 18, 2024

Argenx stock soars to all-time high of $555.55 amid robust growth - Investing.com

Oct 18, 2024

Argen X Se Adr Stock (ARGX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$245.44
price up icon 2.75%
$113.08
price up icon 1.56%
$176.50
price up icon 1.02%
$359.58
price down icon 0.16%
$39.39
price down icon 0.43%
Cap:     |  Volume (24h):